48 studies found for:    " January 27, 2010":" February 26, 2010"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Show Display Options
Rank Status Study
21 Completed Fractures Stratified by HIV and Antiretroviral Therapy (ART) Status
Conditions: Fracture;   Infection, Human Immunodeficiency Virus
Interventions: Other: No Antiretroviral (ARV) Drug Exposure;   Drug: Any Antiretroviral (ARV) Drug Exposure
22 Active, not recruiting Post-Licensure Safety Study of ISENTRESS™ in a US Managed Care Network (MK-0518-268)
Condition: HIV-1 Infections
Intervention:
23 Completed PENTA Fosamprenavir Study
Condition: Infection, Human Immunodeficiency Virus
Intervention: Drug: Exposure to licensed dose of FPV (+/- 20% of 18mg/kg BID + RTV)
24 Completed
Has Results
Evaluation of Kaletra Therapy Over the Long-term
Condition: Human Immunodeficiency Virus
Intervention: Drug: Lopinavir/Ritonavir (Kaletra)
25 Recruiting Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Condition: Human Immunodeficiency Virus
Intervention:
26 Completed
Has Results
Drug Use Investigation of Kaletra
Condition: Human Immunodeficiency Virus
Intervention: Drug: Lopinavir/ritonavir (Kaletra)
27 Recruiting Kaletra in Combination With Antiretroviral Agents
Condition: Human Immunodeficiency Virus
Intervention:
28 Completed
Has Results
Special Investigation of Kaletra in Pregnant Women
Condition: Human Immunodeficiency Virus
Intervention: Drug: Lopinavir/ritonavir (Kaletra)
29 Completed
Has Results
Kaletra: Therapy With Double Protease Inhibitors
Condition: Human Immunodeficiency Virus
Intervention:
30 Completed
Has Results
Long-term Effectiveness and Safety in Hepatitis-co-infected Patients
Condition: Human Immunodeficiency Virus-Infection
Intervention: Drug: Lopinavir/Ritonavir (Kaletra)
31 Completed Patients Infected With HIV Since More Than 10 Years With a Plasma Viral RNA <400 Copies / mL in the Absence of Any Treatment: Study Mechanisms Involved in Controlling the Infection
Condition: HIV Infection
Intervention: Biological: blood test at day one
32 Active, not recruiting Safety and Efficacy Study of AGS-004 During Analytical Treatment Interruption
Condition: HIV Infection
Interventions: Biological: AGS-004;   Biological: Placebo
33 Completed Double-method Comparative Study in Order to Predict the Use of Co-receptors From Type 1 HIV: Phenotypic Study (Trofile ESTA®) and Virologic Response to a CCR5 Antagonist in the Short Term
Condition: HIV Infections
Intervention: Other: Maraviroc + Trofile ESTA® (diagnose test)
34 Unknown  Raltegravir + Lamivudine/Abacavir in HIV/Tuberculosis Co-Infected Patients
Conditions: HIV Infections;   Tuberculosis
Intervention: Drug: Raltegravir; Abacavir/Lamivudine
35 Recruiting Evaluating Strategies to Reduce Mother-to-Child Transmission of HIV Infection in Resource-Limited Countries
Condition: HIV Infections
Interventions: Drug: Zidovudine (ZDV);   Drug: Nevirapine (NVP);   Drug: Emtricitabine-tenofovir disoproxil fumarate (Truvada [TRV]);   Drug: Lamivudine-Zidovudine (3TC-ZDV);   Drug: Lopinavir-ritonavir (LPV-RTV)
36 Active, not recruiting Study of Effects of Tenofovir on Bone Health and Kidneys During Pregnancy and Breastfeeding
Condition: HIV Infections
Intervention: Drug: Tenofovir disoproxil fumarate (TDF)
37 Active, not recruiting Long-Term Outcomes in HIV-Infected Infants, Children, and Adolescents
Condition: HIV Infections
Intervention:
38 Completed Evaluation of the Public Health Interest of Kaletra: Impact on Resistance to Antiretrovirals (ARVs)
Condition: HIV Infection
Intervention:
39 Completed
Has Results
Clinical, Virological and Safety Outcomes of a Lopinavir/Ritonavir-Based Regimen in HIV-1 Infected Patients in Routine Clinical Use in China
Condition: HIV-1 Infections
Intervention: Drug: Lopinavir/ritonavir (Kaletra)
40 Enrolling by invitation Surveillance of Kaletra in Korean Patients
Condition: HIV-1 Infection
Intervention:

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-48) Show next page of results
Indicates status has not been verified in more than two years